

Clinical Trial Protocol

Iranian Registry of Clinical Trials

31 May 2026

The efficacy comparison of Agomelatin and sertraline on depressive episode, in patients with bipolar I disorder

Protocol summary

Study aim

Comparison of the efficacy of sertraline and agomelatine on the depressive phase of bipolar I patients

Design

A clinical trial with a control group with a double-blind and random intervention group in phase 3, on 30 patients, where the intervention group with the letter A and the control group with the letter B are randomly separated.

Settings and conduct

It is performed in Kashan and in the office of the main researcher and among the patients referred to the psychiatric hospital and introduced from the psychiatrist's office. Patients are informed about the research and the type of drug used and explain the existence of a control group without knowing whether it is in the main intervention group or in the control group and that the researcher himself is unaware of the contents of the packages and people in the groups.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Bipolar I patients in the depressive phase, people 18 to 65 years old with bipolar depression, no other mental problems, no medication in the last 3 months
No entry criteria: Psychotic, manic, pregnant and lactating patients, and people with suicidal ideation

Intervention groups

The intervention group is treated with Agomelatine, which is monitored regularly after starting the drug, and during the face-to-face visits and telephone calls, the treatment process and clinical changes, as well as the possible occurrence of side effects, are closely monitored. In the control group, they also receive Sertraline and are monitored and controlled with the same accuracy as the intervention group.

Main outcome variables

The rate of decrease in depression score - Hamilton score - in the two groups treated with sertraline is different from the group treated with agomelatine.

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200803048284N1**

Registration date: **2020-11-04, 1399/08/14**

Registration timing: **retrospective**

Last update: **2020-11-04, 1399/08/14**

Update count: **0**

Registration date

2020-11-04, 1399/08/14

Registrant information

Name

Hamidreza Vojgani

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 31 5533 4489

Email address

dr.hamidrezavojgani@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-09-27, 1399/07/06

Expected recruitment end date

2020-10-31, 1399/08/10

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The efficacy comparison of Agomelatin and sertraline on depressive episode, in patients with bipolar I disorder

Public title

Comparison of the effect of Agomelatine and Sertraline on bipolar depression

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

- Patients with bipolar I disorder in the depression phase based on the Hamilton scale and clinical interview based on the criteria of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Age: 65-18 No liver disease or no impaired liver test. Do not consume drugs and alcohol - Do not have serious neurological problems (epilepsy, dementia, multiple sclerosis, cerebrovascular accidents) and other psychiatric disorders (obsessive-compulsive disorder or anxiety disorders and post-traumatic stress disorder)

Exclusion criteria:

Existence of psychotic manifestations Existence of mania demonstrations Patients with suicidal ideation Pregnancy and lactation

Age

From **18 years** old to **65 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

Sample size

Target sample size: **30**

Randomization (investigator's opinion)

Not randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

In our study, the two groups of participants selected by the researcher of the project, and the caregiver and executor are unaware of which group of participants are receiving what kind of medicine, so that after selecting people and dividing them into two groups, the drug The same packages in size and shape, distinguished by the Latin letters A&B, are provided to the participating groups by the caretaker, who is also unaware of the contents of the packages.

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of Kashan University of Medical Sciences

Street address

Kashan, km 3, Qutb Ravandi Blvd., Physician Blvd.

City

Kashan

Province

Isfahan

Postal code

8715988141

Approval date

2020-07-27, 1399/05/06

Ethics committee reference number

IR.KAUMS.MEDNT.REC.1399.060

Health conditions studied

1

Description of health condition studied

Bipolar Depression I

ICD-10 code

F31/4

ICD-10 code description

Bipolar Depression I

Primary outcomes

1

Description

Improve depressive symptoms and depression score based on the Hamilton scale

Timepoint

Depression scores are measured on a Hamilton scale at baseline and before medication, as well as at 2,4,6,8 weeks.

Method of measurement

Using the Hamilton scale

Secondary outcomes

empty

Intervention groups

1

Description

Bipolar I patients who are in a depressive phase and are being treated with Agomelatine are given Agomelatine tablets from Tadbir Kala Pharmaceutical Company at a

dose of 25 mg only at bedtime for 8 weeks along with one 500 mg Rahakin tablet from Raha Daroo company or 600 mg (two 300 mg tablets) lithium carbonate from Alhawi Pharmaceutical Company is given orally at bedtime.

Category

Treatment - Drugs

2**Description**

Bipolar I patients who are in the depressive phase and are treated with Sertraline are given orally for 8 weeks Sertraline tablets from Dr. Abidi Pharmaceutical Company at a dose of 50 mg daily along with one 500 mg Rahakin tablet from Raha Daroo company or 600 mg (two 300 mg tablets) lithium carbonate from Alhawi Pharmaceutical Company is given orally at bedtime.

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Dr. Afshin Ahmadvand's office

Full name of responsible person

Dr. Afshin Ahmadvand

Street address

Shahid Beheshti

City

Kashan

Province

Isfahan

Postal code

8719653363

Phone

+98 31 5545 5410

Email

ahmadvand_a@kaums.ac.ir

2**Recruitment center****Name of recruitment center**

Kargarnejad Psychiatric Hospital

Full name of responsible person

Dr. Afshin Ahmadvand

Street address

Kashan, km 3, Qutb Ravandi Boulevard, at the end of Parstar Boulevard

City

Kashan

Province

Isfahan

Postal code

8715973446

Phone

+98 31 5554 9111

Fax

+98 31 5554 0036

Email

Kargarnejad@kaums.ac.ir

Web page address

http://Kargarnejad.kaums.ac.ir

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Kashan University of Medical Sciences

Full name of responsible person

Dr. Hamidreza Banafsheh

Street address

Kashan, km 3, Qutb Ravandi Blvd., Physician Blvd.

City

Kashan

Province

Isfahan

Postal code

8715988141

Phone

+98 31 5554 2999

Fax

+98 31 5557 5057

Email

research@kaums.ac.ir

Web page address

http://research.kaums.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Kashan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Kashan University of Medical Sciences

Full name of responsible person

Hamid Reza Vajgani

Position

resident

Latest degree

Medical doctor

Other areas of specialty/work

Psychiatrics

Street address

Alghadir Blvd

City

Kashan

Province

Isfahan

Postal code

8719653363

Phone

003155334489

Email

dr.hamidrezavojgani@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Kashan University of Medical Sciences

Full name of responsible person

Hamidreza Vojgani

Position

Rezident

Latest degree

Medical doctor

Other areas of specialty/work

Psychiatrics

Street address

Ghotbe ravandi Bld kargarnegad hospital

City

Kashan

Province

Isfahan

Postal code

8719653363

Phone

+98 31 5533 4489

Fax

Email

dr.hamidrezavojgani@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Kashan University of Medical Sciences

Full name of responsible person

Hamidreza Vojgani

Position

Rezident

Latest degree

Medical doctor

Other areas of specialty/work

Psychiatrics

Street address

Ghotbe ravandi Bld kargarnegad hospital

City

Kashan

Province

Isfahan

Postal code

8719653363

Phone

+98 31 5533 4489

Fax

Email

dr.hamidrezavojgani@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

There is no more information

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

Not applicable

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available